期刊
CURRENT OPINION IN CHEMICAL BIOLOGY
卷 38, 期 -, 页码 17-23出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.cbpa.2017.02.007
关键词
-
资金
- Bill and Melinda Gates Foundation [OPP1031406]
- Novo Nordisk
- Bayer
- NIH [R01 HL107904, R01 HL109442]
- Bill and Melinda Gates Foundation [OPP1031406] Funding Source: Bill and Melinda Gates Foundation
After approval of the first plant-made biopharmaceutical by FDA for human use, many protein drugs are now in clinical development. Within the last decade, significant advances have been made in expression of heterologous complex/large proteins in chloroplasts of edible plants using codon optimized human or viral genes. Furthermore, advances in quantification enable determination of in-planta drug dosage. Oral delivery of plastid-made biopharmaceuticals (PMB) is affordable because it eliminates prohibitively expensive fermentation, purification processes addressing major challenges of short shelf-life after cold storage. In this review, we discuss recent advances in PMBs against metabolic, inherited or infectious diseases, and also mechanisms of post-translational modifications (PTM) in order to increase our understanding of functional PMBs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据